不可逆电穿孔消融中危前列腺癌组织的PRESERVE试验结果
PRESERVE试验评估NanoKnife系统不可逆电穿孔(IRE)消融中危前列腺癌组织的安全性和有效性。121例患者12个月视野内活检阴性率为71%(95%CI 62%-79%),Delphi共识标准下为84%(95%CI 76%-90%)。IRE安全有效,对排尿和性功能影响较小。
要点
- IRE消融后12个月活检阴性率71%,Delphi标准下达84%。
- PSA中位下降68.2%(6个月时),中位达最低点时间3.5个月。
- 12%患者出现≥3级不良事件,3例为手术相关3级事件。
核心结论
- NanoKnife系统IRE消融对中危前列腺癌患者安全有效。
研究设计与样本
- 前瞻性、非随机、单臂关键性试验(NCT04972097),纳入美国121例中危前列腺癌患者。
主要发现
- 12个月视野内活检阴性率为71%(95%CI 62%-79%)。
- Delphi共识标准下活检阴性率为84%(95%CI 76%-90%)。
- PSA中位达最低点时间3.5个月,6个月时PSA中位下降68.2%。
- 12个月时84%基线性功能良好患者维持足以插入的勃起。
关键数值与推荐
- 纳入标准:年龄>50岁,器官局限Grade Group 2或3,临床分期≤T2c,PSA≤15 ng/ml或PSA密度<0.15 ng/ml2。
临床怎么用
- IRE可作为中危前列腺癌组织消融的安全有效选择,对排尿和性功能影响较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The PRESERVE study (NCT04972097) assessed the safety and effectiveness of irreversible electroporation (IRE) with the NanoKnife System to ablate prostate tissue in patients with intermediate-risk prostate cancer (PCa). METHODS: This prospective, nonrandomized, single-arm pivotal trial included patients in the USA who met the key inclusion criteria: age >50 yr with organ-confined, grade group 2 or 3 PCa, clinical stage ≤T2c, prostate-specific antigen (PSA) ≤15 ng/ml, or PSA density <0.15 ng/ml2. The primary endpoints were the rate of local pathological complete response (negative in-field biopsy) and the incidence, type, and severity of adverse events by 12 mo. The secondary endpoints included PSA kinetics, changes in prostate volume, retreatment, and urinary/sexual function. KEY FINDINGS AND LIMITATIONS: Of the 121 patients treated with IRE, the negative in-field biopsy rate at 12 mo was 71% (95% confidence interval [CI]: 62%, 79%). The secondary endpoint of negative in-field biopsy rate defined by the Delphi consensus criterion was 84% (95% CI: 76%, 90%). The time to median PSA nadir was 3.5 mo, and the median percent reduction in PSA at 6 mo was 68.2%. Urinary function outcomes had a mean change from baseline to 12 mo of 3 in the University of California Los Angeles Expanded Prostate Cancer Index Composite urinary domain total score and a mean change of -2 in the International Prostate Symptom Score total symptom score. At 12 mo, 84% of patients with good baseline sexual function maintained erections sufficient for penetration. Fourteen (12%) patients experienced Common Terminology Criteria for Adverse Events grade ≥3 and three experienced procedure-related grade 3 adverse events. CONCLUSIONS AND CLINICAL IMPLICATIONS: IRE with the NanoKnife System is safe and effective for prostate tissue ablation.
引用
- George AK, Miocinovic R, Patel AR, et al. Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial. Eur Urol. 2025. PMID: 40685282. doi:10.1016/j.eururo.2025.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。